ONC
BeOne Medicines Ltd.
$270.80
+0.26%
$29.8B
No data for this timeframe.
Vol
Market Cap$29.8B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders5 funds
Inst. Value$1.5B
Inst. Activity1 buys / 0 sells
Insider Activity0B / 9S
Insider Net $-$868.4K
SEC Reports2
Recent Activity
Jun 3, 2026
clinical_trial_readout
Results Pending: Tislelizumab (Phase 3) — Completed 11d ago
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advan
Jun 1, 2026
Insider
Yi Qingqing sold 235 shares
Director @ $279.13 ($65.6K)
May 27, 2026
SEC
Two directors at BeOne Medicines sold a combined $131K in open-market transactions on May 22, 2026. The total value repr
CLUSTER — Impact 2/10
May 22, 2026
Insider
Sanders Corazon (Corsee) D. sold 212 shares
Director @ $309.59 ($65.6K)
May 22, 2026
Insider
Dugan Margaret sold 212 shares
Director @ $309.60 ($65.6K)
Feb 26, 2026
SEC
BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and
8-K — Impact 8/10
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
8,400 shares ($2.6M)
Inst.
MORGAN STANLEY — ADD
353,294 shares ($120.4M)
Price Targets
$412.35
+53.8% upside
Strong Buy
Current $268.17
Low $333.00
Median $412.00
High $501.30
27 analysts
$333.00
$501.30
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 15, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 7, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.59 ▲ +23.3% | $1.08 — $2.13 | 90% YoY | 12 |
| Next Q | $1.73 ▲ +11.3% | $1.03 — $2.37 | 58% YoY | 12 |
| Current FY | $6.59 ▲ +1.9% | $5.42 — $8.55 | 160% YoY | 16 |
| Next FY | $9.72 ▲ +1.5% | $5.28 — $13.17 | 47% YoY | 16 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two directors at BeOne Medicines sold a combined $131K in open-market transactions on May 22, 2026. The total value repr
May 27, 2026
BULLISH
8-K
8/10
BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and
Feb 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $1.2B | ADD |
| MORGAN STANLEY | $133.0M | ADD |
| BANK OF AMERICA CORP | $115.1M | — |
| WELLS FARGO & COMPANY/MN | $15.6M | — |
| TWO SIGMA INVESTMENTS, LP | $2.6M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Yi Qingqing | SELL | $65.6K |
| May 22, 2026 | Sanders Corazon | SELL | $65.6K |
| May 22, 2026 | Dugan Margaret | SELL | $65.6K |
| May 22, 2026 | Riva Alessandro | SELL | $65.6K |
| May 22, 2026 | BAKER BROS. | SELL | $65.4K |
5 institutional holders with $1.5B total value (4,869,014 shares) as of 2025-Q4. Top holders: FMR, MORGAN, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 3,992,627 | $1.2B | 82.0% | ADD +86.9% |
| 2 | MORGAN STANLEY | 437,661 | $133.0M | 9.0% | ADD +31.6% |
| 3 | BANK OF AMERICA CORP /DE/ | 378,832 | $115.1M | 7.8% | — |
| 4 | WELLS FARGO & COMPANY/MN | 51,494 | $15.6M | 1.1% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 8,400 | $2.6M | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 8,400 | — | $2.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 268,474 | 353,294 | +31.6% | $120.4M | 2025-Q3 |
| UBS Group AG | TRIM | 181,515 | 104,915 | -42.2% | $35.7M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 411,929 | 268,474 | -34.8% | $65.0M | 2025-Q2 |
| UBS Group AG | DOUBLED | 65,101 | 181,515 | +178.8% | $43.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 104,466 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | ADD | 1,848,063 | 3,453,576 | +86.9% | $940.0M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 334,813 | 1,004,661 | +200.1% | $273.4M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 738,140 | 411,929 | -44.2% | $112.1M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 104,466 | — | $28.4M | 2025-Q1 |
| UBS Group AG | TRIM | 91,468 | 65,101 | -28.8% | $17.7M | 2025-Q1 |
| NORGES BANK | EXIT | 100,006 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 173,032 | 738,140 | +326.6% | $136.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 54,534 | 334,813 | +514.0% | $61.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 35,724 | 91,468 | +156.0% | $16.9M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 85,833 | 173,032 | +101.6% | $38.8M | 2024-Q3 |
10 unique insiders with 9 transactions. Net insider value: -$868.4K ($0.00 bought, $868.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Yi Qingqing | Director | SELL | 235 | $279.13 | $65.6K |
| May 22, 2026 | Sanders Corazon (Corsee) D. | Director | SELL | 212 | $309.59 | $65.6K |
| May 22, 2026 | Dugan Margaret | Director | SELL | 212 | $309.60 | $65.6K |
| May 22, 2026 | Riva Alessandro | Director | SELL | 212 | $309.51 | $65.6K |
| May 22, 2026 | BAKER BROS. ADVISORS LP | Director | SELL | 2,743 | $23.85 | $65.4K |
| May 13, 2026 | Lee Chan Henry | SVP, General Counsel | SELL | 332 | $310.72 | $103.2K |
| May 13, 2026 | Lee Chan Henry | SVP, General Counsel | M | 101 | $194.47 | $19.6K |
| May 13, 2026 | Lee Chan Henry | SVP, General Counsel | M | 1,313 | $0.00 | $0.00 |
| Apr 8, 2026 | Lee Chan Henry | SVP, General Counsel | M | 101 | $194.47 | $19.6K |
| Apr 8, 2026 | Lee Chan Henry | SVP, General Counsel | SELL | 332 | $311.59 | $103.4K |
| Apr 8, 2026 | Lee Chan Henry | SVP, General Counsel | M | 1,313 | $0.00 | $0.00 |
| Mar 11, 2026 | Lee Chan Henry | SVP, General Counsel | M | 1,430 | $0.00 | $0.00 |
| Mar 11, 2026 | Lee Chan Henry | SVP, General Counsel | M | 110 | $194.47 | $21.4K |
| Mar 11, 2026 | Lee Chan Henry | SVP, General Counsel | SELL | 341 | $300.00 | $102.3K |
| Mar 6, 2026 | OYLER JOHN | Chief Executive Officer | A | 326,976 | $0.00 | $0.00 |
| Mar 6, 2026 | Lee Chan Henry | SVP, General Counsel | A | 65,390 | $0.00 | $0.00 |
| Mar 6, 2026 | Rosenberg Aaron | Chief Financial Officer | A | 79,014 | $0.00 | $0.00 |
| Mar 6, 2026 | Wu Xiaobin | President and COO | A | 168,922 | $0.00 | $0.00 |
| Mar 6, 2026 | Wang Lai | President, Global Head of R&D | A | 112,606 | $0.00 | $0.00 |
| Feb 4, 2026 | Lee Chan Henry | SVP, General Counsel | M | 502 | $194.47 | $97.6K |
| Feb 4, 2026 | Lee Chan Henry | SVP, General Counsel | SELL | 664 | $348.79 | $231.6K |
| Feb 4, 2026 | Lee Chan Henry | SVP, General Counsel | M | 6,526 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$412.35 mean target
+53.8% upside
Strong Buy (1.36)
$333.00 Low
$501.30 High
| Metric | Value |
|---|---|
| Current Price | $268.17 |
| Target Low | $333.00 |
| Target Mean | $412.35 |
| Target Median | $412.00 |
| Target High | $501.30 |
| # Analysts | 27 |
| Recommendation | Strong Buy (1.36) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.59 | $1.08 | $2.13 | 89.6% | +23.3% | 8↑ 1↓ | $1.6B | 21.2% | 12 |
| Next Q 2026-09-30 |
$1.73 | $1.03 | $2.37 | 58.3% | +11.3% | 4↑ 5↓ | $1.7B | 18.1% | 12 |
| Current FY 2026-12-31 |
$6.59 | $5.42 | $8.55 | 160.5% | +1.9% | 10↑ 2↓ | $6.5B | 21.3% | 16 |
| Next FY 2027-12-31 |
$9.72 | $5.28 | $13.17 | 47.4% | +1.5% | 9↑ 4↓ | $7.4B | 14.8% | 16 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.592 | |
| 7d ago | $1.592 | |
| 30d ago | $1.291 | +0.301 |
| 60d ago | $1.315 | +0.277 |
| 90d ago | $1.309 | +0.284 |
8 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 15, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 7, 2026 | Truist Securities | REITERATE | Buy | Buy |
| May 4, 2026 | Wells Fargo | INITIATE | — | Overweight |
| Mar 27, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 27, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
Clinical Trial
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Phase Phase 3 — COMPLETED
Jun 3, 2026
clinical_trial_readout
Results Pending: Tislelizumab (Phase 3) — Completed 11d ago
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P
May 13, 2026
FDA
BEGALZI
Original Approval — Type 1 - New Molecular Entity — TABLET
Apr 20, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P
Apr 16, 2026
short_interest
FTD: ONC — 10,000 shares ($3.2M) failed to deliver
Settlement: 20260416, Price: $319.94, FTD Value: $3,199,400, BEONE MEDICINES LTD. AMERICAN
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P
Apr 2, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P
Mar 13, 2026
short_interest
FTD: ONC — 2,864 shares ($0.8M) failed to deliver
Settlement: 20260313, Price: $285.30, FTD Value: $817,099.2, BEONE MEDICINES LTD. AMERICAN
Mar 11, 2026
short_interest
FTD: ONC — 3,585 shares ($1.1M) failed to deliver
Settlement: 20260311, Price: $305.39, FTD Value: $1,094,823.15, BEONE MEDICINES LTD. AMERICAN
Feb 26, 2026
short_interest
FTD: ONC — 1,576 shares ($0.6M) failed to deliver
Settlement: 20260226, Price: $352.23, FTD Value: $555,114.48, BEONE MEDICINES LTD. AMERICAN
Feb 9, 2026
short_interest
FTD: ONC — 14,246 shares ($5.0M) failed to deliver
Settlement: 20260209, Price: $353.92, FTD Value: $5,041,944.32, BEONE MEDICINES LTD. AMERICAN
Feb 3, 2026
short_interest
FTD: ONC — 15,045 shares ($5.2M) failed to deliver
Settlement: 20260203, Price: $345.00, FTD Value: $5,190,525, BEONE MEDICINES LTD. AMERICAN